Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02164045 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Effect of Food on the Pharmacokinetics of BMS-626529
A Phase 1 study, sponsored by ViiV Healthcare.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT02164045 is a Phase 1 study that has completed, run by ViiV Healthcare. The registered enrollment target is 38 participants.
The verdict
NCT02164045, a Phase 1 study, has completed, sponsored by ViiV Healthcare.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
The current food effect study is being performed to support a Phase 3 study with BMS 663068. Results from this study will inform whether patients in the upcoming Phase 3 study can be given the flexibility to dose BMS-663068 in the fasted state, if so desired.
Interventions
- DRUG BMS-663068
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2014-06-24 |
| Est. Completion | 2014-07-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02164045
The ClinicalTrials.gov registry entry for NCT02164045 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BMS-663068 is the first listed.
NCT02164045 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02164045 about?
NCT02164045 is a clinical study titled "Study to Evaluate the Effect of Food on the Pharmacokinetics of BMS-626529". The current food effect study is being performed to support a Phase 3 study with BMS 663068. Results from this study will inform whether patients in the upcoming Phase 3 study can be given the flexibility to dose BMS-663068 in the fasted state, if so desired.
What is the current status of trial NCT02164045?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2014-06-24. Estimated completion is 2014-07-25.
What interventions are being tested in trial NCT02164045?
The interventions under investigation include: BMS-663068 (DRUG).
Who is sponsoring clinical trial NCT02164045?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.